Brief: Acorda Therapeutics Enters Into License Agreement With Asieris Pharmaceuticals
29/08/2022 12:06
Aug 29 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS ENTERS INTO LICENSE AGREEMENT WITH
ASIERIS
PHARMACEUTICALS
* ACORDA THERAPEUTICS- WILL RECEIVE AN UPFRONT PAYMENT OF
$500,000, AND UP TO AN ADDITIONAL $7 MILLION BASED ON
ACHIEVEMENT OF REGULATORY MILESTONES
* ACORDA WILL ALSO RECEIVE A ROYALTY ON FUTURE NET SALES
Source text for Eikon: ID:nBw39tsnPa
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease